Novira Therapeutics gets $11m first tranche of Series A for capsid-targeting antivirals
This article was originally published in Scrip
Novira Therapeutics, a small Radnor, Pennsylvania-based antiviral drug discovery firm with oral capsid-targeting medicines in development for large indications, has raised the first $11 million of a two-tranche, $23 million Series A financing round to advance small molecules for the treatment of hepatitis B virus (HBV) and HIV into the clinic.
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.